Jagsonpal Pharmaceuticals Ltd vs Shukra Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 17, 2026

Key Highlights

The Latest Trading Price of Jagsonpal Pharmaceuticals Ltd is ₹ 206.5 as of 15 May 15:30 . The P/E Ratio of Jagsonpal Pharmaceuticals Ltd changed from 12.2 on March 2021 to 25.9 on March 2025 . This represents a CAGR of 16.25% over 5 yearsThe P/E Ratio of Shukra Pharmaceuticals Ltd changed from 37.1 on March 2021 to 99.3 on March 2025 . This represents a CAGR of 21.76% over 5 years The Market Cap of Jagsonpal Pharmaceuticals Ltd changed from ₹ 208.41 crore on March 2021 to ₹ 1433 crore on March 2025 . This represents a CAGR of 47.06% over 5 yearsThe Market Cap of Shukra Pharmaceuticals Ltd changed from ₹ 6.97 crore on March 2021 to ₹ 956.77 crore on March 2025 . This represents a CAGR of 167.62% over 5 years The revenue of Jagsonpal Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Shukra Pharmaceuticals Ltd for the Mar '26 is ₹ 7.27 crore as compare to the Dec '25 revenue of ₹ 39.95 crore. This represent the decline of -81.8% The ebitda of Jagsonpal Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Shukra Pharmaceuticals Ltd for the Mar '26 is ₹ 1.65 crore as compare to the Dec '25 ebitda of ₹ 27.95 crore. This represent the decline of -94.1% The net profit of Jagsonpal Pharmaceuticals Ltd changed from ₹ 0 crore to ₹ 0 crore over 6 quarters. This represents a CAGR of 0.0% The net profit of Shukra Pharmaceuticals Ltd changed from ₹ 3.16 crore to ₹ -1.72 crore over 6 quarters. This represents a CAGR of NaN% The Dividend Payout of Jagsonpal Pharmaceuticals Ltd changed from 15.36 % on March 2021 to 29.99 % on March 2025 . This represents a CAGR of 14.32% over 5 yearsThe Dividend Payout of Shukra Pharmaceuticals Ltd changed from 10.47 % on March 2022 to 4.57 % on March 2025 . This represents a CAGR of -18.72% over 4 years .

About Jagsonpal Pharmaceuticals Ltd

Promoted by Rajpal Singh Kochhar in August, 1978, Jagsonpal Pharmaceuticals Limited is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana.
The Company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs.
Simultaneously, it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd. The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India.
It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product.
In 1994, the company has also promoted Aresco Financial Services, a new financial company.

About Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Limited, formerly known Relish Pharmaceuticals Limited was established in March, 1993 and later on the Company name was changed from Relish Pharmaceuticals Limited to Shukra Pharmaceuticals Limited effective on September 22, 2016.
The Company is presently engaged in the business of manufacturing and trading of pharmaceuticals formulations and laboratory testing. The company provides varieties of products to the clientele.
Their product portfolio includes Antibiotics (Penicillin), Anti Biotics (Cephalosporin), Anti Biotics, Macrolides, Quinolones, Anti Bacterial, Anti Fungal, Anti Malarial, Anti Viral, Anti Protozoal, Anti Anthelmintic, Sedative and Tranquilliser, Anti Depressant, Anti Manic, Anti Emetic, Anti Ulcer, Beta Blockers, Diuretics, Analgesic, Analgesic (NASID), Muscle Relaxants, Anti Tuberculosis, Vitamin Products, Anti Allergics, Corticosteroids, Hyper and Hypoglycemic, Others.

FAQs for the comparison of Jagsonpal Pharmaceuticals Ltd and Shukra Pharmaceuticals Ltd

Which company has a larger market capitalization, Jagsonpal Pharmaceuticals Ltd or Shukra Pharmaceuticals Ltd?

Market cap of Jagsonpal Pharmaceuticals Ltd is 1,386 Cr while Market cap of Shukra Pharmaceuticals Ltd is 1,374 Cr

What are the key factors driving the stock performance of Jagsonpal Pharmaceuticals Ltd and Shukra Pharmaceuticals Ltd?

The stock performance of Jagsonpal Pharmaceuticals Ltd and Shukra Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Jagsonpal Pharmaceuticals Ltd and Shukra Pharmaceuticals Ltd?

As of May 17, 2026, the Jagsonpal Pharmaceuticals Ltd stock price is INR ₹206.5. On the other hand, Shukra Pharmaceuticals Ltd stock price is INR ₹31.4.

How do dividend payouts of Jagsonpal Pharmaceuticals Ltd and Shukra Pharmaceuticals Ltd compare?

To compare the dividend payouts of Jagsonpal Pharmaceuticals Ltd and Shukra Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.